Q2 2026 United Therapeutics Corp Earnings Call Transcript

Aug 5, 2026 / 01:00 PM GMT

Release Date Price: €446.1 (+0.13%)

Transcript 8-K10-Q

Key Points

Positve

United Therapeutics Corp (UTHR) reported exceptional clinical results from its advanced outcomes study, demonstrating ralinepag's potential as a major new oral therapy for PAH.
The company submitted two important new drug applications to the FDA: an sNDA for nebulized Tyvaso in IPF and an NDA for ralinepag in PAH, with potential approvals expected in 2027.
Tyvaso DPI showed growth and exited the quarter with record levels of starts, referrals, tolls, and commercial patients, indicating strong underlying momentum.
The company has a deep and differentiated organ pipeline, including xenotransplantation programs (Kidney Expand, UKidney, and UKHeart studies), which could create significant long-term growth opportunities.
United Therapeutics Corp (UTHR) expanded its sales force by roughly double in early July, which is expected to increase physician engagement and support stronger commercial performance in the second half of the year.

Negative

United Therapeutics Corp (UTHR) generated approximately $783 million in total revenue in Q2 2026, which was essentially flat with the first quarter and below company expectations.
Nebulized Tyvaso revenue remained pressured by increased competition within the inhaled prostacyclin category, as patients and providers evaluate more treatment options.
The company did not reaffirm any prior revenue growth expectations for 2026, signaling uncertainty about near-term financial performance.
The path to achieving the previously projected $4 billion revenue run rate by the end of 2027 has narrowed, requiring contributions from anticipated IPF and ralinepag launches.
The launch of Tyvaso in IPF will initially be limited to the nebulized formulation, as regulatory approval for DPI and SMI devices in that indication is still pending further FDA engagement.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

UTHR.OQ - United Therapeutics Corporation
Q2 2026 United Therapeutics Corp Earnings Call
Aug 05, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
To the United Therapeutics Corporation second quarter 2020.

My name is JL and I'll be a conference operator today.

All participants on the call portion of this webcast will be in a listen-only mode until the question-and-answer portion of the earnings call.

If you'd like to ask a question again during this time, simply pressar, then the number one on your telephone keypad.

If you'd like to withdraw your questions, you could press star 1 again.

Please note that this call is being recorded.

I now turn the webcast over to Harry Silvers investor relations at United Therapeutics.

Thank you, JL, good morning everyone.

It is my pleasure to welcome

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.